IMAB

I-Mab

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 0

consensus rating "Strong Buy"

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About IMAB

I-Mab

A Chinese biotech company that develops innovative therapies for cancer and autoimmune diseases

Industry

Biological Technology

Established Date

06/30/2016

Listing Date

01/17/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.i-mabbiopharma.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

2440 Research Boulevard, Suite 400, Rockville, MD 20850, United States

Business

Discover, develop and commercialize new or highly differentiated biological agents

Introduction

I-Mab was incorporated in the Cayman Islands on June 30, 2016. It is an innovative biopharmaceutical company in the clinical stage. The company focuses on early detection, drug development and commercialization of innovative biopharmaceuticals in the field of tumor immunity and autoimmune diseases to fill major unmet medical needs. The company's mission vision is to "continuously develop innovative biopharmaceuticals to truly change the lives of patients. ". In order to seize the opportunity and fulfill its mission, under the two-wheel strategy of "rapid product launch" and "rapid proof of concept", Tianjing Bio will focus on the development of preclinical and clinical-stage innovative biological drugs in the two therapeutic areas of tumor immunity and autoimmune diseases through diversified models such as independent research and development and global cooperation. Through independent research and development and the introduction of global projects, we have quickly established more than ten innovative drug pipelines with global competitiveness. Among them, three independent research and development projects have entered Phase I clinical trials in the United States and China, and four projects are in Phase II and Phase III clinical trials in China, respectively.

Company Financials

EPS

IMAB has released its 2024 Q4 earnings. EPS was reported at -0.06, versus the expected -0.05, missing expectations. The chart below visualizes how IMAB has performed over recent quarters, highlighting trends in earnings surprises.